Tepkinly

Imported from official source

Announcement

Safety Classified by Officially

Tepkinly Active substance Epcoritamab Holder AbbVie Belgium SA/NV Status Running Indication Epcoritamab in combination with lenalidomide and rituximab (R²) for the treatment of relapsed or refractory Follicular Lymphoma (FL), previously treated with at least 1 line of systemic chemoimmunotherapy (2L+). …

This is an extract. The publication continues at the source.

Read the original at the source: https://www.famhp.be/fr/usage_humain/medicaments/medicaments/recherche_developpement/usage_compassionnel_programmes_133

Officially imported this from Federal Agency for Medicines and Health Products (FAMHP)’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Federal Agency for Medicines and Health Products (FAMHP) — imported from official source
Official source
https://www.famhp.be/en/rss.xml RSS
Imported
October 03, 2026 20:37
Versions
1 recorded
Identity
110400 at https://www.famhp.be

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.